CAS 403656-89-3

Formula: C32H45F5O3S

InChI: InChI=1S/C32H45F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-27,29,38H,2-10,13-20H2,1H3/t22-,26-,27+,29-,30+,41?/m1/s1

InChI key: KQDQOVMMZCHGQS-YCCWCITDSA-N

SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F

17-Keto Fulvestrant

CAS: 403656-89-3

Formula: C₃₂H₄₅F₅O₃S

Colore e forma: White To Off-White Solid

Peso molecolare: 604.76

Ref: 4Z-F-317

Fulvestrant 17-Ketone

Prodotto controllato

CAS: 403656-89-3

Applications Fulvestrant 17-Ketone, is an impurity of Fulvestrant (F862500), a novel steroidal estrogen antagonist reported to lack any partial agonist activity. Antineoplastic (hormonal).
References Wakeling, A.E., et al.: Cancer Res., 51, 3867 (1991), Howell, A., et al.: Br. J. Cancer, 74, 300 (1996), Robertson, J.F., et al.: Cancer Res., 61, 6739 (2001),

Formula: C₃₂H₄₅F₅O₃S

Colore e forma: Neat

Peso molecolare: 604.75

Ref: TR-F862535

Fulvestrant 17-Ketone-D2

Prodotto controllato

CAS: 403656-89-3

Applications Fulvestrant 17-Ketone-D2 is an intermediate used in the synthesis of Fulvestrant-d3 (F862502), which is novel labelled steroidal estrogen antagonist reported to lack any partial agonist activity. Antineoplastic (hormonal).
References Wakeling, A.E., et al.: Cancer Res., 51, 3867 (1991), Howell, A., et al.: Br. J. Cancer, 74, 300 (1996), Robertson, J.F., et al.: Cancer Res., 61, 6739 (2001),

Formula: C₃₂D₂H₄₃F₅O₃S

Colore e forma: Neat

Peso molecolare: 606.767

Ref: TR-F862536

17-Keto Fulvestrant

CAS: 403656-89-3

Formula: C₃₂H₄₅F₅O₃S

Peso molecolare: 604.76

Ref: ST-EA-CP-F24017